[go: up one dir, main page]

WO2001034177A3 - Method of treating a viral infection using antagonists of macrophage colony stimulating factor - Google Patents

Method of treating a viral infection using antagonists of macrophage colony stimulating factor Download PDF

Info

Publication number
WO2001034177A3
WO2001034177A3 PCT/US2000/030850 US0030850W WO0134177A3 WO 2001034177 A3 WO2001034177 A3 WO 2001034177A3 US 0030850 W US0030850 W US 0030850W WO 0134177 A3 WO0134177 A3 WO 0134177A3
Authority
WO
WIPO (PCT)
Prior art keywords
csf
treating
viral infection
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030850
Other languages
French (fr)
Other versions
WO2001034177A2 (en
Inventor
Kathleen A Clouse-Strebel
Joseph Kutza
Marion F Gruber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
US Department of Health and Human Services
Original Assignee
National Institutes of Health NIH
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, US Department of Health and Human Services filed Critical National Institutes of Health NIH
Priority to AU17595/01A priority Critical patent/AU1759501A/en
Publication of WO2001034177A2 publication Critical patent/WO2001034177A2/en
Publication of WO2001034177A3 publication Critical patent/WO2001034177A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method is provided for treating a viral infection of a cell associated with increased production of M-CSF including contacting the cell with a concentration of M-CSF antagonist sufficient to inhibit replication of the virus. A method is also disclosed for treating a viral infection associated with increased production of macrophage colony stimulating factor (M-CSF), including administering to a subject a therapeutically effective amount of M-CSF antagonist that inhibits replication of the virus. In addition, a method is provided for treating a subject infected with an immunodeficiency virus including administering to the subject a therapeutically effective amount of anti-retroviral drug and co-administering to the subject a therapeutically effective amount of an antagonist of M-CSF. A pharmaceutical composition is provided for the treatment of a viral infection associated with an increased production of M-CSF, including a therapeutically effective amount of an M-CSF antagonist and a pharmaceutically acceptable carrier. The pharmaceutical composition may also include an anti-retroviral drug.
PCT/US2000/030850 1999-11-08 2000-11-07 Method of treating a viral infection using antagonists of macrophage colony stimulating factor Ceased WO2001034177A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17595/01A AU1759501A (en) 1999-11-08 2000-11-07 Method of treating a viral infection using antagonists of macrophage colony stimulating factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16405799P 1999-11-08 1999-11-08
US60/164,057 1999-11-08

Publications (2)

Publication Number Publication Date
WO2001034177A2 WO2001034177A2 (en) 2001-05-17
WO2001034177A3 true WO2001034177A3 (en) 2002-01-31

Family

ID=22592791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030850 Ceased WO2001034177A2 (en) 1999-11-08 2000-11-07 Method of treating a viral infection using antagonists of macrophage colony stimulating factor

Country Status (2)

Country Link
AU (1) AU1759501A (en)
WO (1) WO2001034177A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
AU2011248083B2 (en) 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
CN107257806B (en) 2014-12-22 2021-08-10 戊瑞治疗有限公司 anti-CSF1R antibodies for the treatment of PVNS
LT3283527T (en) 2015-04-13 2021-03-25 Five Prime Therapeutics, Inc. COMPREHENSIVE THERAPY FOR THE TREATMENT OF CANCER
MX2020002301A (en) 2017-09-13 2020-07-13 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009400A1 (en) * 1989-02-10 1990-08-23 Cetus Corporation M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
WO1995024904A1 (en) * 1994-03-16 1995-09-21 Tanox Biosystems, Inc. Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
US5866114A (en) * 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009400A1 (en) * 1989-02-10 1990-08-23 Cetus Corporation M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
US5866114A (en) * 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
WO1995024904A1 (en) * 1994-03-16 1995-09-21 Tanox Biosystems, Inc. Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERGAMINI A ET AL: "Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding.", BLOOD, (1994 NOV 15) 84 (10) 3405-12., XP001002789 *
GRUBER M F ET AL: "Endogenous macrophage CSF production is associated with viral replication in HIV-1-infected human monocyte-derived macrophages.", JOURNAL OF IMMUNOLOGY, (1995 MAY 15) 154 (10) 5528-35., XP002169741 *
KUTZA J ET AL: "Macrophage colony - stimulating factor antagonists inhibit replication of HIV-1 in human macrophages.", JOURNAL OF IMMUNOLOGY, (2000 MAY 1) 164 (9) 4955-60., XP002169742 *
MIRE-SLUIS A R ET AL: "An anti-cytokine bioactivity assay for interferons-alpha, -beta and -omega", JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 195, no. 1, 9 September 1996 (1996-09-09), pages 55 - 61, XP004021254, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO2001034177A2 (en) 2001-05-17
AU1759501A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
EA200200812A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING LOW DOSE OF ENTEKAVIR, AND ITS APPLICATION
WO2001034177A3 (en) Method of treating a viral infection using antagonists of macrophage colony stimulating factor
JP2002523370A5 (en)
JPH02184628A (en) Curing for arthritis disease and inflammation disease
NO20014519L (en) Apomorphine and Sildenafil Preparation
BG106095A (en) NEW MEDICINAL COMPOSITIONS BASED ON ANTICHLINERGY ACTIVE COMPOUNDS AND BETA-MIMETITIS
WO2002034284A3 (en) Methods of therapy for hiv infection
CY1107262T1 (en) TREATMENT OF DEPENDENCE ADDITION
MY127670A (en) Pegylated interferon alfa-ccr5 antagonists combination hiv therapy
JP2002528502A5 (en)
EP1575595A1 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
WO1996011005A3 (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
RU98111152A (en) The use of the active substance flupirtine or its pharmacologically acceptable salts as a drug for the prevention and treatment of diseases associated with damage to the cell system
US20100311656A1 (en) Treatment or prevention of respiratory viral infections with alpha thymosin peptides
DE69328667D1 (en) COMPOSITION CONTAINING FLAVOPEREIRINE AND THEIR USE IN THE TREATMENT AGAINST HIV VIRUSES
CA2368352A1 (en) Method for treating neurodegeneration
JP2003523385A5 (en)
RU2005112720A (en) PHARMACEUTICAL COMPOSITIONS FOR THE IMPROVED ADMINISTRATION OF PEPTIDES ORIGINING FROM GP41 HIV, AND THEIR USE IN THERAPY
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
KR950702838A (en) Method for inhibiting HIV replication using IL-4 using interleukin-4 (IL-4)
JP2002527397A5 (en)
SE8804640L (en) MEDICINAL COMPREHENSIVE CYCLOLINOPEPTIDE A
RU2003106417A (en) APPLICATION OF A VITAMIN COMBINATION FOR TREATMENT OF PRIMARY HEAD PAIN
RU2023121182A (en) USE OF 1-(2-(1H-IMIDAZOLE-4-YL)ETHYL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF COUGH CAUSED BY VIRAL INFECTIONS
Weber et al. Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase